EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-SA 4.0

Design of Cyclodextrin-Based Sustained Release Formulation of Benzbromarone: A Step toward Improved Management of Gout

Eknath D. Ahire, Sanket S. Pawar, Sanjay J. Kshirsagar, Rajendra T. Mogal, Khemchand R. Surana

Ars Pharmaceutica (Internet) · 20.06.2026 · 67 (3) · 284-298

DOI: 10.30827/ars.v67i3.35659 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Ars Pharmaceutica (Internet), online erschienen am 20.06.2026. Verfasst von Eknath D. Ahire und 4 weiteren Autor:innen. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The current study aimed to enhance the bioavailability of benzbromarone through the creation of a sustained-release (SR) tablet, employing β-cyclodextrin complexation to promote solubility and diminish protein binding. Benzbromarone is a uricosuric medication that works by blocking the URAT1 exchanger in the renal proximal tubule. It has low bioavailability since it doesn’t dissolve well in water and binds to proteins strongly.

Methods

The drug-β-cyclodextrin complex was created and made into sustained-release tablets by mixing and matching varying amounts of HPMC K4M and HPMC K100M as matrix-forming polymers. The formulations were tested for pre- and post-compression characteristics, in vitro dissolution, and kinetic modeling.

Results

Formulation F6, which had 10% total polymer concentration (5% HPMC K4M and 5% HPMC K100M), had the best physicochemical qualities and released the most medication for 24 hours (95.71%). Kinetic modeling showed that the release followed zero-order kinetics (R² = 0.9979) and was in line with the Higuchi diffusion model (R² = 0.9784), which points to a diffusion-controlled mechanism.

Conclusion

The results show that β-cyclodextrin considerably improves the solubility and release properties of benzbromarone, making it a viable sustained-release formulation for better gout treatment.

Zitieren

APA

Ahire, E. D., Pawar, S. S., Kshirsagar, S. J., Mogal, R. T., & Surana, K. R. (2026). Design of Cyclodextrin-Based Sustained Release Formulation of Benzbromarone: A Step toward Improved Management of Gout. Ars Pharmaceutica (Internet), 67(3), 284-298. https://doi.org/10.30827/ars.v67i3.35659

Vancouver

Ahire ED, Pawar SS, Kshirsagar SJ, Mogal RT, Surana KR. Design of Cyclodextrin-Based Sustained Release Formulation of Benzbromarone: A Step toward Improved Management of Gout. Ars Pharmaceutica (Internet). 2026;67(3):284-298. doi:10.30827/ars.v67i3.35659

BibTeX
@article{Ahire2026,
  author = {Ahire, Eknath D. and Pawar, Sanket S. and Kshirsagar, Sanjay J. and Mogal, Rajendra T. and Surana, Khemchand R.},
  title = {Design of Cyclodextrin-Based Sustained Release Formulation of Benzbromarone: A Step toward Improved Management of Gout},
  journal = {Ars Pharmaceutica (Internet)},
  year = {2026},
  volume = {67},
  number = {3},
  pages = {284--298},
  doi = {10.30827/ars.v67i3.35659}
}
Kostenlos starten →